EFFECTOR THERAPEUTICS INC (EFTR) Stock Price, Quote, News and Overview
NASDAQ:EFTR - Nasdaq - US28202V2079 - Common Stock - Currency: USD
EFTR Quote, Performance and Key Statistics
0.18
-0.09 (-32.56%)
The current stock price of EFTR is 0.18 USD. In the past month the price decreased by -88.46%. In the past year, price decreased by -99.13%.
EFTR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About EFTR
Company Profile
eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Company Info
EFFECTOR THERAPEUTICS INC
142 North Cedros Avenue, Suite B, Suite A
Solana Beach CALIFORNIA US
CEO: John M. Butler
Employees: 15
Company Website: https://effector.com/
Phone: 18589258215
EFFECTOR THERAPEUTICS INC / EFTR FAQ
What is the stock price of EFFECTOR THERAPEUTICS INC today?
The current stock price of EFTR is 0.18 USD. The price decreased by -32.56% in the last trading session.
What is the ticker symbol for EFFECTOR THERAPEUTICS INC stock?
The exchange symbol of EFFECTOR THERAPEUTICS INC is EFTR and it is listed on the Nasdaq exchange.
On which exchange is EFTR stock listed?
EFTR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EFFECTOR THERAPEUTICS INC stock?
8 analysts have analysed EFTR and the average price target is 11.22 USD. This implies a price increase of 6133.33% is expected in the next year compared to the current price of 0.18. Check the EFFECTOR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EFFECTOR THERAPEUTICS INC worth?
EFFECTOR THERAPEUTICS INC (EFTR) has a market capitalization of 846.00K USD. This makes EFTR a Nano Cap stock.
How many employees does EFFECTOR THERAPEUTICS INC have?
EFFECTOR THERAPEUTICS INC (EFTR) currently has 15 employees.
Should I buy EFFECTOR THERAPEUTICS INC (EFTR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EFTR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EFTR, evaluating the profitability, health, valuation and growth aspects
- EFFECTOR THERAPEUTICS INC (EFTR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EFFECTOR THERAPEUTICS INC (EFTR) Sales and EPS estimates to see what analysts future expectations are.
- EFFECTOR THERAPEUTICS INC (EFTR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EFFECTOR THERAPEUTICS INC (EFTR) Insider and Institutional Ownership to learn about the owners and their transactions.
- EFFECTOR THERAPEUTICS INC (EFTR) Stock Chart to make your own analysis
- EFFECTOR THERAPEUTICS INC (EFTR) Latest news and press-releases to stay up to date.
Does EFFECTOR THERAPEUTICS INC (EFTR) stock pay dividends?
EFTR does not pay a dividend.
When does EFFECTOR THERAPEUTICS INC (EFTR) report earnings?
EFFECTOR THERAPEUTICS INC (EFTR) will report earnings on 2024-08-06, after the market close.
What is the Price/Earnings (PE) ratio of EFFECTOR THERAPEUTICS INC (EFTR)?
EFFECTOR THERAPEUTICS INC (EFTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.08).
What is the Short Interest ratio of EFFECTOR THERAPEUTICS INC (EFTR) stock?
The outstanding short interest for EFFECTOR THERAPEUTICS INC (EFTR) is 0.13% of its float. Check the ownership tab for more information on the EFTR short interest.
EFTR Technical Analysis
EFTR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EFTR. While EFTR seems to be doing ok healthwise, there are quite some concerns on its profitability.
EFTR Financial Highlights
Over the last trailing twelve months EFTR reported a non-GAAP Earnings per Share(EPS) of -13.08. The EPS decreased by -9.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.64% | ||
| ROE | -4187.55% | ||
| Debt/Equity | 0 |
EFTR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to EFTR. The Buy consensus is the average rating of analysts ratings from 8 analysts.